S
Su Chu
Researcher at City of Hope National Medical Center
Publications - 30
Citations - 2037
Su Chu is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Progenitor cell & Chronic myelogenous leukemia. The author has an hindex of 18, co-authored 30 publications receiving 1869 citations. Previous affiliations of Su Chu include University of Alabama & University of Alabama at Birmingham.
Papers
More filters
Journal ArticleDOI
Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
Bin Zhang,Adam C. Strauss,Su Chu,Min Li,YinWei Ho,Keh-Dong Shiang,David S. Snyder,Claudia S. Huettner,Leonard D. Shultz,Tessa L. Holyoake,Ravi Bhatia +10 more
TL;DR: HDRACi treatment represents an effective strategy to target LSCs in CML patients receiving tyrosine kinase inhibitors and inhibited genes regulating hematopoietic stem cell maintenance and survival.
Journal ArticleDOI
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
TL;DR: It is demonstrated that BCR-ABL(+) stem cells persist in CML patients despite prolonged treatment with imatinib, and support ongoing efforts to target this population.
Journal ArticleDOI
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment
Su Chu,Helen Xu,Helen Xu,Neil P. Shah,Neil P. Shah,David S. Snyder,David S. Snyder,Stephen J. Forman,Stephen J. Forman,Charles L. Sawyers,Charles L. Sawyers,Ravi Bhatia,Ravi Bhatia +12 more
TL;DR: It is concluded that BCR-ABL kinase mutations can be detected in CD34+ cells from CML patients in CCR on imatinib, may contribute to persistence of small populations of malignant progenitors, and could be a potential source of relapse.
Journal ArticleDOI
SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells
Ling Li,Tereza Osdal,YinWei Ho,Sookhee Chun,Tinisha McDonald,Puneet Agarwal,Allen Lin,Su Chu,Jing Qi,Liang Li,Yao-Te Hsieh,Cedric Dos Santos,Hongfeng Yuan,Trung-Quang Ha,Mihaela Popa,Randi Hovland,Øystein Bruserud,Øystein Bruserud,Bjørn Tore Gjertsen,Bjørn Tore Gjertsen,Ya-Huei Kuo,WenYong Chen,Sonia Lain,Emmet McCormack,Emmet McCormack,Ravi Bhatia +25 more
TL;DR: It is shown that the NAD-dependent SIRT1 deacetylase is selectively overexpressed in primary human FLT3-ITD AML LSCs and contributes to their maintenance.
Journal ArticleDOI
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
TL;DR: It is concluded that inhibition of BCR/ABL kinase activity in CML progenitors by imatinib results in a growth factor-dependent compensatory increase in MAPK activity and in only partial inhibition of PI-3 Kinase activity.